Hirayuki Enomoto
Overview
Explore the profile of Hirayuki Enomoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
2018
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Possible Use of Body Surface Area Value for Estimating Skeletal Muscle Mass in Chronic Liver Disease
Yoh K, Nishimura T, Ikeda N, Takashima T, Aizawa N, Yuri Y, et al.
Diagnostics (Basel)
. 2025 Feb;
15(3).
PMID: 39941193
Sarcopenia is an important clinical feature of patients with chronic liver disease (CLD). However, special devices are required to determine skeletal muscle mass. We evaluated the usefulness of body surface...
2.
Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, et al.
Oncology
. 2025 Feb;
:1-23.
PMID: 39900019
Background/aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use of tumor markers as...
3.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39844393
Background And Aim: To assess the relationship between survival outcomes and subtypes of radiological progressive disease (PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atezo/Bev). Methods:...
4.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, et al.
Cancer Med
. 2025 Jan;
14(2):e70618.
PMID: 39840727
Aim: This study aims to investigate the clinical utility of the derived neutrophil-to-lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable...
5.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, et al.
Hepatol Res
. 2024 Nov;
PMID: 39526824
Aim: Since the development of tremelimumab plus durvalumab (Dur/Tre) for unresectable hepatocellular carcinoma (uHCC), it has been used as not only an initial but also later line treatment in clinical...
6.
Liu S, Li J, Wong Y, Yim H, Hirooka M, Enomoto H, et al.
MedComm (2020)
. 2024 Nov;
5(11):e781.
PMID: 39492833
Baveno VII criteria (B7C) and Baveno VI criteria (B6C) have been widely used to estimate the risk of hepatic decompensation. However, the impact of age on these criteria warrants further...
7.
Yuri Y, Nishimura T, Ikeda N, Takashima T, Aizawa N, Kimura T, et al.
In Vivo
. 2024 Oct;
38(6):2968-2972.
PMID: 39477391
Background/aim: Gastroesophageal varices (GEV) hemorrhage is a serious complication that can lead to unfavorable outcomes in cirrhotic patients. However, the clinical impact of HCV elimination [sustained viral response (SVR)] by...
8.
Nakano R, Shiomi H, Okamoto M, Kawase Y, Yoshihara K, Yoshioka R, et al.
Diagnostics (Basel)
. 2024 Oct;
14(19).
PMID: 39410637
Background/objectives: Covered self-expandable metallic stents (CSEMS) are commonly used to treat malignant distal biliary obstructions. A 10-mm CSEMS carries the risk of obstructing the pancreatic and cystic duct orifices by...
9.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1361-1373.
PMID: 39233317
Aim: This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them...
10.
Liu C, You H, Zeng Q, Wong Y, Wang B, Grgurevic I, et al.
Clin Mol Hepatol
. 2024 Jul;
31(1):105-118.
PMID: 38988296
Backgrounds/aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol...